In contrast to the efficacy data of the mRNA-based coronavirus vaccines developed by Modern (NASDAQ: MRNA) and Pfizer (NYSE: PFE), which was approximately 95% effective in keeping coronavirus infections at bay, Johnson & Johnson’s (NYSE: JNJ) the results of the vaccine may not have inspired much optimism. The company’s adenovirus vector vaccine has been shown to be 66% effective in preventing moderate to severe COVID-19 in phase 3 trials.
But once we look deeper, the vaccine data is incredibly promising. Not to mention, there are many logistical reasons why a single-dose vaccine can be a big winner. Johnson & Johnson has vowed not to favor the vaccine during the pandemic, but once the public health crisis disappears, the health giant could still get loot. That’s why “66%” is not the red flag you would think.